Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Hong Kong · Delayed Price · Currency is HKD

5.65

0.00 (0.00%)

Oct 9, 2026, 3:53 PM HKT

Market Cap	1.35B -55.4%
Revenue (ttm)	1.50B -0.5%
Net Income	161.05M +13.0%
EPS	0.66 +5.2%
Shares Out	240.03M
PE Ratio	8.53
Forward PE	n/a
Dividend	0.07 (1.16%)
Ex-Dividend Date	Jun 17, 2026

Volume	11,200
Open	5.65
Previous Close	5.65
Day's Range	5.33 - 5.65
52-Week Range	4.60 - 12.71
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixin... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 1,787

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2566

Full Company Profile

Financial Performance

In 2025, HKG:2566's revenue was 1.31 billion, a decrease of -4.59% compared to the previous year's 1.37 billion. Earnings were 138.41 million, a decrease of -0.14%.

Financial numbers in CNY Financial Statements